# EDGAR Filing Document

**Accession Number:** 0001492422
**File Stem:** 0001127602-25-019265
**Filing Date:** 2025-7
**Character Count:** 8874
**Document Hash:** 88f95ca49882efb75f283b72ac6d7ae9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001127602-25-019265.hdr.sgml**: 20250716

**ACCESSION NUMBER**: 0001127602-25-019265

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250714

**FILED AS OF DATE**: 20250716

**DATE AS OF CHANGE**: 20250716

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Francois Cedric
- **CENTRAL INDEX KEY:** 0001658080

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38276
- **FILM NUMBER:** 251127586

**MAIL ADDRESS:**
- **STREET 1:** 6400 WESTWIND WAY
- **STREET 2:** SUITE A
- **CITY:** CRESTWOOD
- **STATE:** KY
- **ZIP:** 40014
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apellis Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001492422
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271537290
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 FIFTH AVENUE
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 617-977-5700

**MAIL ADDRESS:**
- **STREET 1:** 100 FIFTH AVENUE
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Francois Cedric<br><sub>(Last) (First) (Middle)</sub><br>C/O APELLIS PHARMACEUTICALS, INC.<br>100 FIFTH AVENUE, 3RD FLOOR<br><sub>(Street)</sub><br>WALTHAM, MA 02451<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-14 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Apellis Pharmaceuticals, Inc. [ APLS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-07-14 |  | M<sup>(1)</sup> |  | 65203 | A | $4.31 | 480898 | D |  |
| Common Stock | 2025-07-14 |  | S<sup>(1)</sup> |  | 137465 | D | 20.1864<sup>(2)</sup> | 343433 | D |  |
| Common Stock | 2025-07-15 |  | M<sup>(1)</sup> |  | 800 | A | $4.31 | 344233 | D |  |
| Common Stock | 2025-07-15 |  | S<sup>(1)</sup> |  | 1900 | D | 20.0884<sup>(3)</sup> | 342333 | D |  |
| Common Stock |  |  |  |  |  |  |  | 532946 | I<sup>(4)</sup> | Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) |
| Common Stock |  |  |  |  |  |  |  | 472065 | I<sup>(5)</sup> | Indirect Owner (The Cedric Francois Irrevocable Trust of 2023) |
| Common Stock |  |  |  |  |  |  |  | 300000 | I<sup>(6)</sup> | Indirect Owner (The Francois Grossi Trust) |
| Common Stock |  |  |  |  |  |  |  | 234411 | I<sup>(7)</sup> | Indirect Owner (The Francois-DuBois Educational Trust) |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $4.31 | 2025-07-14 |  | M<sup>(1)</sup> |  |  | 65203 | <sup>(8)</sup> | 2027-08-20 | Common Stock | 65203 | $0 | 110335 | D |  |
| Stock Option (Right to Buy) | $4.31 | 2025-07-15 |  | M<sup>(1)</sup> |  |  | 800 | <sup>(8)</sup> | 2027-08-20 | Common Stock | 800 | $0 | 109535 | D |  |

---

### Footnotes:

(1) This is a scheduled exercise & sale from 10b5-1 trading plan dated March 10, 2025.

(2) This transaction was executed in multiple trades at prices ranging from $20 - $20.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.

(3) This transaction was executed in multiple trades at prices ranging from $20 - $20.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.

(4) The securities are held by The Cedric Francois Irrevocable Trust of 2023 - 2. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023 - 2. The reporting person disclaims beneficial ownership over the      shares held by The Cedric Francois Irrevocable Trust of 2023 - 2 except to the extent of his pecuniary interest therein.

(5) The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.

(6) The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.

(7) The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.

(8) This option was granted on August 21, 2017 and is fully vested.

**Signature:** /s/ David Watson, attorney-in-fact for Cedric Francois  
**Date:** 2025-07-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**